Newcastle disease live vaccine adjuvant and preparation method thereof
The invention provides a newcastle disease live vaccine adjuvant. The newcastle disease live vaccine adjuvant comprises the following raw materials in percentage by weight: 60-75% of a buffer solution, 5%-10% of squalane, 5%-10% of squalene, 3%-5% of pluronic, 1%-3% of an emulsifier, 2%-4% of hydroxymethyl cellulose, 2%-4% of dimethyl dioctadecyl ammonium bromide and 1%-3% of polycaprolactone. Theadjuvant composition can remarkably improve humoral immune response and cellular immune response of the newcastle disease vaccine, not only can generate a relatively high antibody level in a short time, but also can stimulate an organism to generate efficient protective force for a long time, when the adjuvant composition is used for preparing vaccines, large emulsification equipment is not needed, the vaccine preparation process is stable, and the side reaction after vaccine immunization is small..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 07. Aug. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHU YALU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111494621 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005723140 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005723140 | ||
| 003 | DE-627 | ||
| 005 | 20230504135430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005723140 | ||
| 035 | |a (EPA)CN111494621 | ||
| 035 | |a (EPA)71848853 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHU YALU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newcastle disease live vaccine adjuvant and preparation method thereof |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention provides a newcastle disease live vaccine adjuvant. The newcastle disease live vaccine adjuvant comprises the following raw materials in percentage by weight: 60-75% of a buffer solution, 5%-10% of squalane, 5%-10% of squalene, 3%-5% of pluronic, 1%-3% of an emulsifier, 2%-4% of hydroxymethyl cellulose, 2%-4% of dimethyl dioctadecyl ammonium bromide and 1%-3% of polycaprolactone. Theadjuvant composition can remarkably improve humoral immune response and cellular immune response of the newcastle disease vaccine, not only can generate a relatively high antibody level in a short time, but also can stimulate an organism to generate efficient protective force for a long time, when the adjuvant composition is used for preparing vaccines, large emulsification equipment is not needed, the vaccine preparation process is stable, and the side reaction after vaccine immunization is small. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 07. Aug. |
| 773 | 1 | 8 | |g year:2020 |g day:07 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71848853/publication/CN111494621A1?q=CN111494621 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 07 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 07 |c 08 | ||